Ayse Kaplan*

Faculty of Science, Department of Molecular Biology, Eskisehir Technical University, Eskisehir, Turkey

*Corresponding Author: Ayse Kaplan, Molecular Biologist, Faculty of Science, Department of Molecular Biology, Eskisehir Technical University, Eskisehir, Turkey.

Received: February 23, 2023; Published: February 24, 2022

Nanomedicine has emerged as a major field of academic research with direct impact on human health [1]. Rapid growth in nanotechnology towards the improvement of nanomedicine products commits great prospect to develop therapeutic strategies against cancer. Nanomedicine products represent an opportunity to get advanced targeting strategies and multi-functionality [2]. Nanomedicine assists in maintaining a balance between efficacy and toxicity by specifically accumulating in tumors [3]. The advances in nanotechnology as well as cancer biology have enhanced improvement of drug delivery systems for cancer management with enhanced efficacy and limited side effects. Among them, a variety of nanomaterials based on natural/synthetic polymers, liposomes, metal-organic frameworks (MOFs), gold nanoparticles (NPs) and silica NPs have been used to co-deliver cancer agents and other therapeutics with purpose reducing drug side effects [4].

References

1. Ragelle H., et al. “Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures”. Expert Opinion Drug Delivery 14(7) (2017):851-864.
2. Wicki A., et al. “Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications”. Journal of Controlled of Release 200 (2015):138-157.
3. Hejmady S., et al. “Recent advances in targeted nanomedicine as promising antitumor therapeutics”. Drug Discovery Today 25(2020): 2227-2244.
4. Yu S., et al. “Advances in nanomedicine for cancer starvation therapy”. Theranostics 9(26)(2019):8026-8047.
5. Shi J., et al. “Cancer nanomedicine: progress, challenges and opportunities”. Nature Reviews Cancer 17(2017):20-37.
6. Rasool M., et al. “New challenges in the use of nanomedicine in cancer therapy”. Bioengineered 13(1)(2022):759–773.
7. Raza F., et al. “Recent advances in the targeted delivery of paclitaxel nanomedicine for cancer therapy”. Materials Advances 3(2022):2268-2290.
8. Cheng Y., and Ji Y. “Mitochondria-targeting nanomedicine self-assembled from GSH-responsive paclitaxel-ss-berberine conjugate for synergetic cancer treatment with enhanced cytotoxicity”. Journal of Controlled Release 318(2020):38–49.
9. Kumar P., et al. “Promises of phytochemical based nano drug delivery systems in the management of cancer”. Chemico-Biological Interactions 351(2022):e109745.
10. Chavda VP., et al. “Phytochemical-loaded liposomes for anticancer therapy: an updated review”. Nanomedicine 17 (2022):547-568.

Citation

Citation: Ayse Kaplan. “Nanomedicine in Cancer Therapy: Recent Advances and Perspectives" Acta Scientific Cancer Biology 7.1 (2023): 20-21.

Copyright

Copyright: © 2022 Ayse Kaplan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.